Hematology/Oncology Pharmacy Association (HOPA) | Strategic Alliance Partners

Understanding the role of abemaciclib (Verzenio) in managing patients with hormone receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer is crucial.

Amid rising cancer care costs, a focus on chemotherapy stewardship may result in cost savings, according to a session of the HOPA Practice Management 2020 Virtual Learning Event.

In outpatient breast cancer clinics, oral chemotherapies are becoming more common for various malignancies, but hematologic and non-hematologic toxicities can cause challenges for patients.

Oral oncolytics has become increasingly common as treatment for patients with cancer over the past several years.

The objective of the study was to develop an education program that increased confidence and knowledge of pharmacists managing CDK4/6 inhibitors.

In the oral chemotherapy setting, pharmacist care exceeded patients’ expectations and helped manage and avoid adverse events (AEs).

Kirollos Hanna, PharmD, BCPS, BCOP, explains antibody drug conjugates and their method of action. This video was filmed at the Hematology/Oncology Pharmacists Association 2020 Meeting in Tampa, Florida.

Pharmacy Times will be on-site next week to provide coverage of the sessions, recaps of the panel discussions, and interviews with the experts.